First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT07527923
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • REGN20423 — DRUG
    Administered per the protocol
  • Placebo — OTHER
    Administered per the protocol

Study Details

This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans. The study is looking at: * What side effects REGN20423 might cause * How much REGN20423 is in the blood at different times * How well REGN20423 works in adults with atopic dermatitis * Whether the body makes antibodies against REGN20423 * How the body changes after having REGN20423, which can help researchers understand why REGN20423 works better in some people than others * What the best dose of REGN20423 is

Key Dates

First listed
Apr 14, 2026
Start date
May 22, 2026
Status verified
Jun 2026
Primary completion
Jun 23, 2028
Completion
Jun 23, 2028

Study Design

Enrollment
144 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A
  • Experimental: Part B

Primary Outcome Measure

Occurrence of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 69 weeks ]

Central Contacts

Find similar trials

Nationwide
Atopic dermatitis / eczema trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies